Table 5 Schedule of evaluation points
| Â | EP 1.0 | EP 1.1 | EP 1.2 | EP 1.3 | EP 1.999 |
|---|---|---|---|---|---|
| Â | Screening | After 24 hours | After 72 hours | Weekly | After discharge |
Screening | Â | Â | Â | Â | Â |
Inclusion and Exclusion criteria | • | • |  |  |  |
Informed consent |  |  | ° | ° | ° |
Demography | Â | Â | Â | Â | Â |
Age, Gender |  |  |  |  | • |
History | • |  |  |  |  |
Laboratory examinations | Â | Â | Â | Â | Â |
TSH, TT4, FT4, TT3, FT3 |  | • | • | • |  |
rT3 |  |  | • |  |  |
Total protein, Albumin |  | • | • | • |  |
BC, CRP, ATIII, Fibrinogen |  | • | • | • |  |
Thyroid antibodies, T4/T3-Abs. |  | • |  |  |  |
Other investigations |  | • | • | • |  |
Temperature, Horowitz-Quotient | Â | Â | Â | Â | Â |
Vital signs | • | • | • | • |  |
Evolution data | Â | Â | Â | Â | Â |
Medication | • | • | • | • | • |
APACHE-II-/SAPS-II-Score, GCS |  | • | • | • | • |
Diagnosis |  | • |  |  | • |
HD/CVVH/CVVHDF | • | • | • | • | • |
IABP | • | • | • | • | • |
Persistent organ failure |  |  |  |  | • |
Outcome (survival etc.) |  |  |  |  | • |
| Â | EP 2.0 | EP 2.1 | EP 2.2 | EP 2.3 | Â |
| Â | After transfer to peripheral ward | After 3 months | After 6 months | After 1 year | Â |
History and clinical data | Â | Â | Â | Â | Â |
Burch-Wartofsky score | ° | ° |  |  |  |
Medication | ° | ° | ° | ° |  |
Vital signs | ° | ° | ° | ° |  |
Laboratory examinations | Â | Â | Â | Â | Â |
TSH, TT4, FT4, TT3, FT3 | ° | ° |  |  |  |
Neuropsychological data | Â | Â | Â | Â | Â |
Number connection test | ° | ° |  |  |  |
RWT | ° | ° |  |  |  |
SKT | ° | ° |  |  |  |
HADS | ° |  |  |  |  |
SF36 |  | ° | ° | ° |  |
Other investigations | Â | Â | Â | Â | Â |
Thyroid ultrasonography | ° | ° |  |  |  |
Outcome (survival etc.) | ° | ° | ° | ° |  |